GeneDx (NASDAQ: WGS) — Perfil da empresa, notícias e dados financeiros
GeneDx specializes in genomic analysis and testing for rare disorders, cancers, and neurology, enhancing patient care.
GeneDx
GeneDx (NASDAQ:WGS) specializes in genomic analysis and testing, offering advanced solutions to enhance patient care by deciphering complex genetic information. Its operations focus on leveraging cutting-edge genomics to facilitate early diagnosis and personalized treatment strategies, particularly for rare disorders, cancers, and neurological conditions. With a robust portfolio of projects, GeneDx aims to integrate precision medicine into routine healthcare, making in-depth genetic insights accessible to a wider patient base. Their objective is to empower clinicians with precise diagnostic tools and actionable data, thereby improving outcomes and quality of life for patients around the globe.
Resumo
Operações
Produtos e/ou serviços de GeneDx
- Whole Exome Sequencing (WES) - Offers detailed analysis of all protein-coding genes to diagnose rare genetic conditions.
- Genetic Counseling Services - Provides personalized counseling on genetic testing results and implications.
- Prenatal Screening Tests - Early detection options for chromosomal abnormalities in fetuses.
- Custom Panel Testing - Tailored genetic tests for specific conditions or families' unique genetic concerns.
- Carrier Screening - Assesses individuals' or couples' risk of passing genetic conditions to offspring.
- Cancer Genetics Testing - Identifies inherited cancer risks and guides personalized treatment plans.
equipe executiva do GeneDx
- Katherine A. StuelandCEO & Director
- Kevin FeeleyChief Financial Officer
- Bryan M. DechairoChief Technology & Innovation Officer
- Mark A. GardnerPresident
- Sabrina V. DunbarDirector of Investor Relations & Communications
- Heidi C. ChenChief Legal Officer
- Jami BiliboacaChief People Officer
- Melanie DuquetteChief Growth Officer
- Lisa GurryChief Business Officer
- Linda GenenChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela GeneDx , em USD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 454,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.6
- Dividend yield
- —
- Margem de lucro
- -23.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 427,5 mi | -11,8 mi | -21 mi | |
| 305,5 mi | -23,2 mi | -52,3 mi | |
| 202,6 mi | -180,6 mi | -175,8 mi | |
| 234,7 mi | -667,7 mi | -549 mi |